Community, Connection, and Sharing the Science at CROI 2025
Experts share here what they take away from the Conference on Retroviruses and Opportunistic Infections (CROI) each year and why this meeting is so important in this space.
Read More
Late-Breaking Antiviral Session Features Phase 3 Results on Efficacy of Doravirine/Islatravir
March 13th 2025The combination of doravirine plus islatravir was noninferior to bictegravir/emtricitabine/tenofovir alafenamide and oral antiretroviral therapy in patients who switched to doravirine plus islatravir.
Read More
Advancing HIV Care With Doravirine and Islatravir: Q&A With Amy Colson, MD, MPH
March 12th 2025New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically suppressed people living with HIV-1, were presented today by Amy Colson, MD, MPH.
Read More
Implementation, Adherence to DoxyPEP Remains Low in At-Risk Groups
March 12th 2025Patients in Washington, DC, and San Francisco had minimal early uptake and adherence to doxycycline postexposure prophylaxis (DoxyPEP) in studies presented at the Conference on Retroviruses and Opportunistic Infections 2025.
Read More
Addressing and Improving Gaps in HIV Care for Children and Adolescents
March 11th 2025Early diagnosis and prompt antiretroviral therapy initiation are critical for children due to the rapid progression of HIV in infants, explains Priscilla Tsondai, MD, MPH, and unlike adults they require age-appropriate formulations, caregiver support, and strategies to ensure adherence.
Read More
Global Status of HIV/AIDS Pandemic Takes Center Stage in Opening Session
March 10th 2025The Conference on Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about the progress, and lack of progress, that has been made in the fight against the HIV pandemic given the current political climate.
Read More
HIVconsvX Vaccine Shows Safety, Immune Response in People on ART
March 10th 2025This research on a T-cell–targeting vaccine in HIV has implications for future study design to incorporate consideration of age and years on antiretroviral therapy (ART) to evaluate the level of immune reconstitution.
Read More